Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.64 |
| ▸ | CLK2 | P49760 | 1/20 | 0.64 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.64 |
| ▸ | CDK8 | P49336 | 3/20 | 0.41 |
| ▸ | CCNC | P24863 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7682924 | 0.87 | CSNK1A1 (0.64) | CSNK1A1CSNK1DCLK2CSNK1G1CDK8 | |
| SCHEMBL7690467 | 0.84 | CSNK1A1 (0.60) | CSNK1A1CSNK1DCLK2CSNK1G1CDK8 | |
| SCHEMBL7682958 | 0.83 | CSNK1A1 (0.59) | CSNK1A1CSNK1DCLK2CSNK1G1CDK8 | |
| SCHEMBL7689435 | 0.82 | CSNK1A1 (0.61) | CSNK1A1CSNK1DCLK2CSNK1G1CDK8 | |
| SCHEMBL7680927 | 0.78 | CSNK1A1 (0.56) | CSNK1A1CSNK1DCLK2CSNK1G1CDK8 | |
| SCHEMBL7685369 | 0.78 | CSNK1A1 (1.00) | CSNK1A1CSNK1DCLK2CSNK1G1CDK8 | |
| SCHEMBL7682818 | 0.77 | CSNK1A1 (0.72) | CSNK1A1CSNK1DCLK2CSNK1G1CDK8 | |
| SCHEMBL7694078 | 0.75 | CSNK1A1 (0.66) | CSNK1A1CSNK1DCLK2CSNK1G1CDK8 | |
| Hydrochloric Acid SCHEMBL7742023 | 0.75 | CSNK1A1 (0.93) | CSNK1A1CSNK1DCLK2CSNK1G1CDK8 | |
| SCHEMBL15076920 | 0.73 | CSNK1A1 (0.50) | CSNK1A1CSNK1DCLK2CSNK1G1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-6417202-B1 | 3-ACETYL-4-METHYL-2,5-DI(4-PYRIDYL)-1H-PYRROLE, FOR EXAMPLE; TREATING CELL ADHESION MOLECULES (CAMS) MEDIATED DISEASES SUCH AS ARTHRITIS, AIDS, SEPTIC SHOCK, CACHEXIA, TRANSPLANT REJECTION | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | CSNK1A1 2764/4885CSNK1D 2846/4885CLK2 3605/4885 |
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | ICAM1, VCAM1, CD14 | CSNK1A1 2321/4885CSNK1D 2460/4885CLK2 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.